Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer
Terumo India has announced the launch of Occlusafe and LifePearl, intended for use in the management of liver cancer.
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, with more than 20,000 cases getting added every year in India. HCC can be treated with management approaches ranging from surgical resection to minimally invasive options.
Embolisation is one such minimally invasive management option. In this, the blood supply to the tumour is blocked. This deprives the tumour of nutrients and oxygen, which induces the death of these tumour cells. The most common type of Embolization is Transcatheter Arterial Chemo-Embolization (TACE), a clinical-guideline recommended, minimally invasive management option for intermediate stage liver cancer.
Terumo, has introduced an advanced therapy called Balloon-TACE (B-TACE) for the management of liver cancer. With Occlusafe, Terumo’s B-TACE device, patients benefit from more precise and targeted delivery of chemotherapy drug to the tumour. Additionally, damage to surrounding healthy tissues is minimised. This is associated with improved response rates, with significantly fewer repeat treatments required versus TACE alone. This offers the potential to preserve liver function.
LifePearl helps release chemotherapeutic drug in a controlled and sustained manner at the targeted tumour site inside the liver.
Occlusafe and LifePearl are known to improve clinical outcomes for liver cancer patients treated with TACE.
Elaborating on the therapy, Shishir Agarwal, MD, Terumo India, said, “At Terumo, our mission is to contribute to society through healthcare. We aim to bring the latest Japanese medical technologies to India to advance the quality of care for patients and physicians. Occlusafe and Lifepearl will offer alternate management options to support liver cancer care in India.”
- Advertisement -